Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Q2 results

- PMLiVE

AstraZeneca and Merck’s Lynparza combination therapy receives FDA priority review in first-line prostate cancer

Prostate cancer is the second most common cancer in male patients in the US, projected to cause around 35,000 deaths in 2022

- PMLiVE

AstraZeneca and Daiichi Sankyo announce results for lung cancer therapy

Initial results for the combination therapy – with Merck’s Keytruda – show an overall response rate of 37% in patients with non-small cell lung cancer

- PMLiVE

Merck and Cerevance to research novel targets in Alzheimer’s disease

The total value of the deal is expected to be around $1.1bn

- PMLiVE

Merck and Cerevance to research novel targets in Alzheimer’s disease

The total value of the deal is expected to be around $1.1bn

- PMLiVE

FDA delays Merck’s pneumococcal vaccine Vaxneuvance

It is predicted that the vaccine could make over $1bn in peak sales

- PMLiVE

How marketers are balancing the changing trends in women’s health

We’ve reached a turning point in the way we view and provide healthcare to women. In the midst of discontent with the way that women are treated in healthcare and...

IGNIFI

- PMLiVE

The power of influence in transforming women’s health

Over the past four years HRT prescriptions have doubled in the UK, the cause was turbo charged by the action of celebrities and influencers.

Say Communications

- PMLiVE

Merck’s Keytruda receives FDA approval for advanced endometrial cancer

The approval was based on new data from the KEYNOTE-158 trial

Thrive webinar on women's health and tech panel discussion

Bridging the gender health gap: 9 key takeaways from Thrive’s webinar on tech and women’s health

Unequal health outcomes have been a reality for women throughout the world for far too long. But change is finally happening.

Thrive Agency

- PMLiVE

Merck and Ridgeback fulfil US deal for molnupiravir

Over three million courses of the investigational oral antiviral COVID-19 treatment have been supplied

- PMLiVE

Merck’s Keytruda combined with chemotherapy could benefit thousands of breast cancer patients

The combination significantly reduces cancer recurrence by approximately 37% and reduces secondary breast cancer by 39%

- PMLiVE

Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment

The study evaluated the combination of Lenvima plus Keytruda versus chemotherapy for patients diagnosed with advanced, metastatic, or recurrent endometrial carcinoma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links